Cargando…
Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort
BACKGROUND: With regard to switching tumor necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA), conflicting results have been reported as to whether the effectiveness of a second TNFi depends on the reason for discontinuation of the first TNFi. METHODS: Patients with a clinical diag...
Autores principales: | Ciurea, Adrian, Exer, Pascale, Weber, Ulrich, Tamborrini, Giorgio, Steininger, Beate, Kissling, Rudolf O., Bernhard, Jürg, Scherer, Almut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802885/ https://www.ncbi.nlm.nih.gov/pubmed/27000865 http://dx.doi.org/10.1186/s13075-016-0969-2 |
Ejemplares similares
-
HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry
por: Fröhlich, Fabienne, et al.
Publicado: (2022) -
Sacroiliac joint radiographic progression in axial spondyloarthritis is retarded by the therapeutic use of TNF inhibitors: 12-year data from the SCQM registry
por: Micheroli, Raphael, et al.
Publicado: (2022) -
Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis
por: Micheroli, Raphael, et al.
Publicado: (2017) -
Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management Registry
por: Popova, Vjara, et al.
Publicado: (2023) -
Comparison of drug survival on adalimumab, etanercept, golimumab and infliximab in patients with axial spondyloarthritis
por: Hebeisen, Monika, et al.
Publicado: (2019)